title: Osteosarcoma. Specific tumor management and results.
abstract: The survival rate of patients with osteogenic sarcoma has greatly improved with the institution of a multidisciplinary approach that combines multi-agent chemotherapy and limb-sparing surgery. Presently, 80% of those patients who do not have distant metastases at presentation will become long-term survivors, compared to 20% prior to 1970. For patients with metastases at diagnosis, or who develop metastases after initiation of treatment, long-term survival is also possible if all primary and metastatic disease is removed. The data presented in this article supports aggressive resection of pulmonary metastases in osteogenic sarcoma patients.
authors.affiliation: Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
authors.forename: M P
authors.initials: MP
authors.lastname: La Quaglia
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001859:Bone Neoplasms; D003131:Combined Modality Therapy; D004724:Endoscopy; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary* / Q000601:surgery; D016609:Neoplasms, Second Primary / Q000601:surgery; D012516:Osteosarcoma / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000556:secondary* / Q000601:surgery; D011013:Pneumonectomy; D015996:Survival Rate; D013906:Thoracoscopy; D013908:Thoracotomy; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome